Publications

  1. Veldic M, Ahmed AT, Blacker CJ, Geske JR, Biernacka JM, Borreggine KL, Moore KM, Prieto ML, Vande Voort JL, Croarkin PE, Hoberg AA, Kung S, Alarcon RD, Keeth N, Singh B, Bobo WV, Frye MA. Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Front Pharmacol. 2019; 10:83 Epub 2019 Feb 19
    View PubMed
  2. Mrazek DA, Biernacka JM, McAlpine DE, Benitez J, Karpyak VM, Williams MD, Hall-Flavin DK, Netzel PJ, Passov V, Rohland BM, Shinozaki G, Hoberg AA, Snyder KA, Drews MS, Skime MK, Sagen JA, Schaid DJ, Weinshilboum R, Katzelnick DJ. Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study. J Clin Psychopharmacol. 2014 Jun; 34 (3):313-7
    View PubMed
  3. Hoberg AA, Vickers KS, Ericksen J, Bauer G, Kung S, Stone R, Williams M, Moore MJ, Frye MA. Feasibility evaluation of an interpersonal and social rhythm therapy group delivery model. Arch Psychiatr Nurs. 2013 Dec; 27 (6):271-7 Epub 2013 Sept 12
    View PubMed
  4. Hoberg AA, Ponto J, Nelson PJ, Frye MA. Group interpersonal and social rhythm therapy for bipolar depression. Perspect Psychiatr Care. 2013 Oct; 49 (4):226-34 Epub 2013 Jan 18
    View PubMed
  5. Hoberg AA, Ponto J. Nelson PF, Frye MA. Group interpersonal and social rhythm therapy for bipolar depression. Perspectives in Psychiatric Care 1111/ppc12008. 2013; doi:10.